Background: Cardiotoxicity development in survivors of acute lymphoblastic leukemia is one of the most serious chronic complications of cancer therapy. Objectives: This study aimed to assess the frequency of doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Methods: We utilized a cross section case-control study design and included 50 ALL survivors attending pediatric oncology clinic for follow up after finishing chemotherapy and 50 age- and sex-matched controls. All participants were subjected to full general examination. The cardiac status was assessed by Echocardiography and Tissue Doppler Technique.Results:. Tissue doppler parameters S" (myocardial systolic velocity) m/sec, E" (early phase of diastole negative velocity) and A” m/sec (late phase of diastole negative velocity) , A (peak early mitral inflow velocity) and E (peak late mitral inflow velocity) wave DT(deceleration time) ,GCS(global circumferential strain) &GLS(global longtudinal strain) were statistically lower among ALL survivor, than controls,but MPI(myocardial performance index) was statistically higher among ALL survivor than controls. Conclusion: Our results demonstrated that all echocardiographic and Tissue Doppler parameters are lower among ALL survivors than controls, except that MPI(myocardial performance index) , LVED (left ventricular end diastolic dimention) and LVES(left ventricular end systolic dimention) is higher among ALL survivors than controls indicating cardiac dysfunction among ALL survivors.